# Amgen MariTide (AMG 133): A Unique GLP-1 Agonist with GIP Antagonism

Canonical source: https://retacompare.com/research/amgen-maritide-amg-133-glp-1-agonist-gip-antagonist

Pipeline Candidates · 2026-05-02


    Amgen's MariTide (AMG 133) represents an innovative approach in obesity treatment, combining GLP-1 agonism with GIP antagonism. This mechanism may inform future quad-agonist designs, positioning it as a noteworthy candidate in the evolving landscape of metabolic therapies.

 The big picture

In the wake of the promising results from Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon, the pharmaceutical landscape is increasingly focused on multi-agonist therapies for obesity and metabolic diseases. MariTide (AMG 133) emerges as a unique contender, employing a dual mechanism that combines GLP-1 receptor agonism with GIP receptor antagonism. This strategy not only aims to enhance weight loss but also seeks to mitigate potential side effects associated with excessive GIP signaling. As the obesity epidemic continues to rise, innovative treatments like MariTide could play a crucial role in addressing this public health challenge.

 How it works

MariTide's mechanism is characterized by its dual action: it activates the GLP-1 receptor while antagonizing the GIP receptor. GLP-1 is well-known for its role in glucose homeostasis and appetite regulation, promoting insulin secretion and reducing appetite. In contrast, GIP is implicated in fat deposition and may contribute to weight gain when overactivated. By combining these two mechanisms, MariTide aims to harness the benefits of GLP-1 while potentially counteracting the adverse effects of GIP, creating a more balanced metabolic response. This approach could inform the design of future quad-agonists, where the modulation of multiple pathways is essential for achieving optimal therapeutic outcomes.

 Key points at a glance

MariTide (AMG 133) is a GLP-1 receptor agonist combined with a GIP receptor antagonist.

This dual mechanism aims to promote weight loss while reducing potential side effects linked to GIP.

It is currently in the pipeline stage, with details on clinical trials still emerging.

The drug's design may influence future quad-agonist therapies targeting multiple metabolic pathways.

Other notable drugs in the multi-agonist space include Retatrutide and Tirzepatide, each with distinct mechanisms.

Amgen's exploration of MariTide reflects a growing trend in obesity treatment focused on multi-receptor engagement.

 Where this fits in the pipeline

MariTide is currently in the early stages of clinical development, with specific trial details not fully disclosed. As of now, it represents a novel approach within Amgen's pipeline, which is increasingly focused on innovative therapies for metabolic conditions. The strategic combination of GLP-1 agonism and GIP antagonism aligns with ongoing research into multi-agonist therapies, although the exact timeline for clinical results remains speculative. The emergence of MariTide alongside other candidates like Retatrutide and Tirzepatide illustrates a dynamic and competitive environment in the field of obesity pharmacotherapy.

 What it could mean for patients

If successful, MariTide could offer a new treatment option for patients struggling with obesity and related metabolic disorders. Its unique mechanism of action may provide benefits beyond what is achievable with existing GLP-1 agonists, potentially leading to improved weight loss outcomes and better metabolic control. However, the clinical impact remains to be fully elucidated, and patient responses will need to be carefully evaluated in forthcoming trials. The balance between efficacy and safety will be crucial in determining MariTide's role in the therapeutic landscape.

 Open questions and what we don't yet know

Despite its potential, several questions remain regarding MariTide's safety, efficacy, and long-term outcomes. The antagonism of GIP could have unforeseen consequences that need to be thoroughly investigated in clinical trials. Additionally, the timeline for regulatory approval and market availability is uncertain, as the drug is still in early clinical stages. Understanding the precise patient populations that may benefit most from MariTide will also be essential for its successful integration into treatment protocols. Further research is needed to explore the full range of pharmacological effects and to establish clear guidelines for its use.

 Bottom line

MariTide (AMG 133) represents a novel approach in the obesity treatment pipeline, combining GLP-1 agonism with GIP antagonism. While it holds promise for enhancing metabolic outcomes, ongoing research will be critical to determine its efficacy and safety.

 This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources